ONO ST 468
Alternative Names: ONO-ST-468Latest Information Update: 28 Apr 2023
At a glance
- Originator Ono Pharmaceutical
- Class Antisecretories; Small molecules
- Mechanism of Action Somatostatin receptor 2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acromegaly
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for preclinical development in Acromegaly in Japan (IV, Infusion)
- 23 Mar 2019 Preclinical trials in Acromegaly in Japan (IV) prior to March 2019
- 23 Mar 2019 Pharmacodynamics data from a preclinical trial in Acromegaly presented at the 101th Annual Meeting of the Endocrine Society (ENDO-2019)